Press Releases

Strengthens global intellectual property position with 13th issued patent covering the company's proprietary technology for the capture and detection of rare cells from biological fluids

Commends CMS for supporting innovation in diagnostics and transparency on future Medicare pricing

New test uses patient's blood sample to profile and monitor for PD-L1 expression, an important biomarker in immuno-oncology treatment decision makingTest developed in collaboration with renowned pathologist David Rimm, MD, PhD, of Yale University School of Medicine

Study data further support the clinical utility and validation of Biocept's CTC and ctDNA tests to profile and monitor biomarker status in patients diagnosed with cancer

Continues to execute on 2016 Company priority with second pharma company agreement

Detecting RET fusions can identify patients who may benefit from targeted therapy with tyrosine kinase inhibitors

Billable sample volume increases 280% year-over-year and marks the fourth consecutive quarter of double-digit sequential growthConference call begins at 4:30 p.m. Eastern time today

This sixth U.S. patent covers unique method used for detection of rare cells including circulating tumor cells

SAN DIEGO , May 5, 2016 /PRNewswire/ --  Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company with a commercialized liquid biopsy technology, Target Selector TM , focused on cancer treatment and monitoring, announces that it will release financial results for the three months

SAN DIEGO , May 2, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company with a commercial liquid biopsy technology focused on cancer treatment and monitoring, announces that management will make a corporate presentation at Joseph Gunnar & Co.'s inaugural